Global C-19 Vaccination Goal and framework for Action

September 2021



RECAP : objective of updated COVID-19 Global Vaccination Strategic Vision

Inform country targets and global vaccination goals for 2022 in light of key uncertainties

2 Promote equitable approach to vaccination globally, as part of broader pandemic control strategy

3 Inform global policymaking & access efforts, investments by financial/donor institutions, R&D groups & manufacturers, and country planning & work




RECAP: Global C19 Vaccination Strategy included broad consultation

ີ Governance	(with eng		GE AG-IH & EC as needed					
ິດ Task Team (10 people)	Working team of technical experts representing a few key stakeholders Sub-workstreams on different technical matters			Key Stakeholders Europe Asia Norway Amb. GH China CDC FCDO India eCDC Thai MoPH Mexico (Instituto del Seguro Soc				
Ad hoc Strategy Group (40 people)	Ieveraging existing modelling groups Broader group providing strategic direction Representatives of all key stakeholders			Africa Afro CDC	Africa Afro CDC African Development Bank AU Nigeria CDC		ceania /ernment f Health	Organizations WHO Gavi CEPI UNICEF World Bank BMGF CSO (incl. MSF)
				Middle East WHO regional office WHO regional offices		offices	IFPMA DCVMN Academics	
	Wider s		nsultation incl. Member					



Process and key timeline for COVID Vaccine Global Vision







Context and need for coordinated approach to vaccination

Disease burden		 250mn+ cases and nearly 5 million deaths¹ of COVID-19 declared Despite rapid Vaccine development, new waves threaten health systems, variants are more transmissible, & serious long-term sequelae reported
Vaccines as	E I	Nearly 6 Bn doses of vaccine already administered
the solution		 Global production is now reaching 1.5 billion doses per month
		 In areas of high coverage, major reductions in serious disease, hospitalization, death
Inequities		 However, the world is not positioned to end the pandemic
		 Access is highly inequitable, ranging from 1% to >70%, depending largely on wealth




- - Variants continue to emerge, causing surges of disease & slowing or reversing reopening of societies & economies; with losses potentially >US\$9 trillion by 2025²

1. reported as of September 2021

2. IMF estimations




Health and socio-economic goals drive the global COVID-19 vaccination goal





1. as evidence become available

COVID-19 vaccination coverage targets



- 70% coverage target driven by health & economic imperatives of rapidly stopping the pandemic; technical analyses on epidemiology & vaccine attributes; and feasibility assessment
- Interim targets of 10% / 40%
 coverage to ensure equitable pace of global vaccine rollout & prioritization of those at highest risk



Rationale for broad coverage

- Immunization of all adults with COVID-19 vaccines will provide substantial and important health returns on investment, is feasible to achieve in all countries with the right investments, is grounded in evidence and is being actively pursued already in many countries;
- Vaccination of adolescents will further reduce disease burden and provide other important benefits towards resuming socio-economic activity, as impact on reducing transmission is fully investigated;
- At-risk investments needed to assure rapid deployment of vaccines while scientific knowledge advances; building necessary financial infrastructure, supply capacity and delivery services takes time;
- The global COVID-19 vaccination effort can be leveraged to strengthen primary health-care systems and other immunization activities.

Note: This broad vaccination scope is underpinned by a thorough technical and feasibility assessment that analyzed: (i) COVI D-19 disease and infection epidemiology, (ii) evolving science on COVID-19 vaccines and SAR CoV-2 virus evolution, (iii) required vaccine doses and global supply, (iv) vaccine and delivery costs, (v) expected health and economic returns on investment, and (vi) political will, financing, supply and programmatic resources.




The global COVID-19 vaccination goal and targets are anchored in following principles

Equity	Quality	Integrated	Inclusivity
All individuals, populations & countries should have equitable access without financial hardship;	Vaccines used should meet international standards through WHO authorization;	Vaccines should be deployed with tests, treatments and public health & social measures;	Vaccination must include marginalized, displaced and vulnerable populations.



Achieving the global COVID-19 vaccination targets requires anticipating and addressing key challenges



Producing an adequate global supply of COVID-19 vaccines

Ensuring sufficient financial and programmatic resources for procurement & delivery

Guaranteeing equitable access to COVID-19 vaccines by all countries, across income groups

Managing risks associated with the emergence of new variants of SARS-CoV-2





Worldwide vaccine need: 11-12 Bn doses



Worldwide gap:5+ Bn doses (6 Bn doses administered to date)Vaccine production :1.5 Bn doses per month



LIC/LMIC total funding/ financing need : \$55 Bn, but much of the vaccine requirement has already been contracted

LICs/LMICs in-country delivery costs : \$15-\$20 Bn, need to be covered through in-kind, domestic, grants, concessional loans

New ACT-A Strategy/Budget planned for release by 15 Oct with more detail on the gap that should be covered through COVAX



Aligned and coordinated action is needed to achieve the global COVID-19 vaccination targets


MDBs and Manufacturers **High Coverage** CSOs Private Sector WHO, Gavi, UNICEF, **All Countries Countries** CEPI Institutions Empower people, Prioritize supply and Establish national plans and communities and transparency to ensure commit to equitable vaccine Ensure COVAX's Ensure sufficient Take urgent actions to partners locally and global equity and share distribution, including free det vaccine doses to success and support end delivering funding and globally to act in support know-how flow of materials and lower coverage countries to end impact for support for procurement of demand and equity through COVAX, AVAT vaccines; thoroughly report equitable, high coverage local data through eJRF and other means <u>00</u>0 [] 00 0 \neg 70% ŚĎ 1/1 000

Transparency and data as critical enabler, from manufacturers on 'place in the queue', bilateral deals and from countries on accurate and complete data reporting

June 2022









Living document

Public release in the near future

Continuously discuss with partners & Member States and refine as new evidence becomes available



